Aarhus University Seal / Aarhus Universitets segl

Peter Vedsted

The European Cancer Patient's Bill of Rights, update and implementation 2016

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

  • Liselotte Højgaard, Faculty of Health and Medical Sciences, Kobenhavns Universitet, Kobenhavns, Denmark.
  • ,
  • Bob Löwenberg, Department of Pediatric Oncology/Hematology, Sophia Children's Hospital-Erasmus University Medical Center, Rotterdam, The Netherlands.
  • ,
  • Peter Selby, Leeds Enterprise Centre, Leeds University
  • ,
  • Mark Lawler, European Cancer Concord, Leeds, UK.
  • ,
  • Ian Banks, Leeds Enterprise Centre, Leeds University
  • ,
  • Kate Law, European Cancer Concord, Leeds, UK.
  • ,
  • Tit Albreht, Institut za varovanje zdravja Republike Slovenija, Ljubljana, Slovenia.
  • ,
  • Jean-Pierre Armand, Institut Gustave Roussy, Villejuif, France.
  • ,
  • Mariano Barbacid, Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • ,
  • Michèle Barzach, IHU Strasbourg Board of Trustees, Strasbourg, France.
  • ,
  • Jonas Bergh, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • ,
  • David Cameron, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, UK.
  • ,
  • Pierfranco Conte, Istituto Oncologico Veneto, Padova, Italy.
  • ,
  • Filippo de Braud, Medical Oncology Division, National Cancer Institute, Milan, Italy.
  • ,
  • Aimery de Gramont, Department of Oncology, Institut Hospitalier Franco-Britannique, Levallois-Perret, France.
  • ,
  • Francesco De Lorenzo, European Cancer Patient Coalition, Brussels, Belgium.
  • ,
  • Volker Diehl, Internal Medicine, Universitat zu Koln, Koln, Germany.
  • ,
  • Sarper Diler, Myeloma Patients Europe, Istanbul, Turkey.
  • ,
  • Sema Erdem, Europa Donna, Milan, Italy.
  • ,
  • Jan Geissler, European Patients Academy on Therapeutic Innovation, Riemerling, Germany.
  • ,
  • Jola Gore-Booth, EuropaColon, London, UK.
  • ,
  • Geoffrey Henning, EuropaColon, London, UK.
  • ,
  • Denis Horgan, European Alliance for Personalised Medicine, Brussels, Belgium.
  • ,
  • Jacek Jassem, Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
  • ,
  • Peter Johnson, Cancer Research UK, London
  • ,
  • Stein Kaasa, Institute of Cancer Research and Molecular Medicine, Norges teknisk-naturvitenskapelige universitet, Trondheim, Norway.
  • ,
  • Peter Kapitein, Inspire2Live, Amsterdam, The Netherlands.
  • ,
  • Sakari Karjalainen, Association of European Cancer Leagues, Brussels, Belgium.
  • ,
  • Joan Kelly, Irish Cancer Society, Dublin, Ireland.
  • ,
  • Anita Kienesberger, Austrian Childhood Cancer Organisation, Vienna, Austria.
  • ,
  • Carlo La Vecchia, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
  • ,
  • Denis Lacombe, Biostatistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium.
  • ,
  • Tomas Lindahl, Francis Crick Institute, Mill Hill Laboratory, London
  • ,
  • Lucio Luzzatto, Università degli Studi di Firenze, Dipartimento di Storia, Archeologia, Geografia, Arte e Spettacolo, 50122 Firenze, Italy
  • ,
  • Rebecca Malby, School of Health and Social Care, London South Bank University, London, UK.
  • ,
  • Ken Mastris, Europa Uomo, Antwerp, Belgium; Oncological Centre, Antwerp, Belgium.
  • ,
  • Françoise Meunier, Biostatistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium.
  • ,
  • Martin Murphy, European Cancer Concord, Society for Translational Oncology, Durham, North Carolina, USA.
  • ,
  • Peter Naredi, Biostatistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium.
  • ,
  • Paul Nurse, Francis Crick Institute, Mill Hill Laboratory, London
  • ,
  • Kathy Oliver, International Brain Tumour Alliance, Tadworth, UK.
  • ,
  • Jonathan Pearce, Lymphoma Association, Aylesbury, UK.
  • ,
  • Jana Pelouchov, European Cancer Patient Coalition, Brussels, Belgium.
  • ,
  • Martine Piccart, Institut Jules Bordet, Bruxelles, Belgium.
  • ,
  • Bob Pinedo, VuMC Cancer Center, Amsterdam, The Netherlands.
  • ,
  • Gilly Spurrier-Bernard, Melanoma Patient Network Europe, Paris, France.
  • ,
  • Richard Sullivan, Institute of Cancer Policy, Kings Health Partners Integrated Cancer Centre, London, UK.
  • ,
  • Josep Tabernero, Oncogenetics Group, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
  • ,
  • Cornelis Van de Velde, Department of Surgery, Leids Universitair Medisch Centrum, Leiden, The Netherlands.
  • ,
  • Bert van Herk, Spaarne Gasthuis, Amsterdam, The Netherlands.
  • ,
  • Peter Vedsted
  • Anita Waldmann, Leukaemiehilfe RHEIN-MAIN, Rüsselsheim, Germany.
  • ,
  • David Weller, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.
  • ,
  • Nils Wilking, Reproductive Medicine Center, Skåne University Hospital, Lund University, Malmö, Sweden.
  • ,
  • Roger Wilson, Sarcoma Patients EuroNet EV, Bad Nauheim, Germany.
  • ,
  • Wendy Yared, Association of European Cancer Leagues, Brussels, Belgium.
  • ,
  • Christoph Zielinski, European Society for Medical Oncology, Lugano, Switzerland.
  • ,
  • Harald Zur Hausen, German Cancer Research Centre, University of Heidelberg, Heidelberg, Germany.
  • ,
  • Thierry Le Chevalier, Inserm, CESP, U1018, Villejuif, France; Univ Paris-Sud, UMRS 1018, Villejuif, France; Gustave Roussy Institute, F-94800 Villejuif, France.
  • ,
  • Patrick Johnston, European Cancer Concord, Leeds, UK.

In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. The key aspects of working towards implementing the BoR are:Agree our high-level goal. The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.

OriginalsprogEngelsk
Artikelnummere000127
TidsskriftESMO Open
Vol/bind1
Nummer6
Antal sider7
ISSN2059-7029
DOI
StatusUdgivet - 2016

Se relationer på Aarhus Universitet Citationsformater

ID: 117569600